Literature DB >> 15862282

Adiponectin and resistin serum levels in women with polycystic ovary syndrome during oral glucose tolerance test: a significant reciprocal correlation between adiponectin and resistin independent of insulin resistance indices.

Krzysztof C Lewandowski1, Konrad Szosland, Chris O'Callaghan, Bee K Tan, Harpal S Randeva, Andrzej Lewinski.   

Abstract

Polycystic ovary syndrome (PCOS) is associated with an increased incidence of insulin resistance (IR), obesity, and type 2 diabetes. Resistin, an adipocytokine, may represent a link between obesity, and these metabolic disorders. There is also evidence that inflammation is a hyperresistinemic state in humans, and cytokine induction of resistin may contribute to insulin resistance in endotoxemia, obesity, and other inflammatory states. In contrast, adiponectin, increases insulin sensitivity, improves glucose tolerance, inhibits inflammatory pathways, while adenovirus-expressed adiponectin reduces atherosclerotic lesions in a mouse model of atherosclerosis. We aimed to assess, in women with PCOS, whether there is a relationship between adiponectin and resistin and the indices of IR, and whether serum levels of these adipocytokines are altered by glucose-induced hyperinsulinaemia. Serum levels of resistin and adiponectin were measured at 0, 60, and 120 min during 75 g oral glucose tolerance test (OGTT), in 19 women with PCOS, age 36.3+/-11.4 years (mean+/-SD), body mass index (BMI) 29.3+/-7.7 kg/m2, and correlated with the indices of IR, such as HOMA-IR, QUICKI, and the insulin resistance index calculated from glucose and insulin levels obtained during OGTT. There was no change in resistin concentrations (7.31+/-4.58, 7.47+/-5.40, 7.22+/-5.12 pg/ml, at 0, 60, and 120 min of OGTT, respectively, P = 0.77), but there was an increase in adiponectin from 11.32+/-4.64 microg/ml at baseline to 14.78+/-7.41 microg/ml, at 120 min of OGTT (P < 0.01). The magnitude of the overall rise in adiponectin was greater from 60 to 120 min (from 12.31+/-5.72 to 14.78+/-7.41 microg/ml, P < 0.006). Neither resistin, nor adiponectin correlated with the indices of IR, lipids, or other hormonal parameters of the PCOS. There was, however, a significant negative correlation between serum resistin and adiponectin (P = 0.001). In conclusion, we observed a strong negative correlation between serum adiponectin and resistin, despite the lack of direct correlation with the indices of IR. Given the opposite effects of resistin and adiponectin on the inflammatory process, we speculate that relative proportion of adiponectin-to-resistin might potentially influence cardiometabolic risk in women with the PCOS independently of IR parameters. The observed increase in adiponectin during OGTT requires further study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15862282     DOI: 10.1016/j.ymgme.2004.12.014

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  17 in total

1.  Total and high-molecular weight adiponectin in women with the polycystic ovary syndrome.

Authors:  Edmond P Wickham; Kai I Cheang; John N Clore; Jean-Patrice Baillargeon; John E Nestler
Journal:  Metabolism       Date:  2010-03-31       Impact factor: 8.694

2.  Low circulating adiponectin levels in women with polycystic ovary syndrome: an updated meta-analysis.

Authors:  Shan Li; Xiamei Huang; Huizhi Zhong; Qiliu Peng; Siyuan Chen; Yantong Xie; Xue Qin; Aiping Qin
Journal:  Tumour Biol       Date:  2014-01-12

Review 3.  Gender differences in cardiovascular disease: hormonal and biochemical influences.

Authors:  Faustino R Pérez-López; Luis Larrad-Mur; Amanda Kallen; Peter Chedraui; Hugh S Taylor
Journal:  Reprod Sci       Date:  2010-06       Impact factor: 3.060

Review 4.  Adiponectin action from head to toe.

Authors:  Karine Brochu-Gaudreau; Charlotte Rehfeldt; Richard Blouin; V Bordignon; Bruce D Murphy; Marie-France Palin
Journal:  Endocrine       Date:  2009-12-01       Impact factor: 3.633

Review 5.  Gender differences in the metabolic syndrome and their role for cardiovascular disease.

Authors:  V Regitz-Zagrosek; E Lehmkuhl; M O Weickert
Journal:  Clin Res Cardiol       Date:  2006-01-30       Impact factor: 5.460

Review 6.  Adiponectin and polycystic ovary syndrome.

Authors:  Susan W Groth
Journal:  Biol Res Nurs       Date:  2010-05-24       Impact factor: 2.522

7.  Effect of a combined estrogen and progesterone oral contraceptive on circulating adipocytokines adiponectin, resistin and DLK-1 in normal and obese female rhesus monkeys.

Authors:  Kate A Shaw; Jon D Hennebold; Alison B Edelman
Journal:  Contraception       Date:  2012-12-04       Impact factor: 3.375

8.  Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide.

Authors:  Xin Tao; Xiao Zhang; Shu-Qi Ge; Er-Hong Zhang; Bin Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

9.  Adiponectin-resistin index and its strong association with acute coronary syndrome in South Indian men.

Authors:  Prerna Singh; M G Sridhar; Medha Rajappa; J Balachander; Tamilarasu Kadhiravan
Journal:  Inflamm Res       Date:  2014-09-14       Impact factor: 4.575

10.  ADIPONECTIN AS A SERUM MARKER OF ADIPOSE TISSUE DYSFUNCTION IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: CORRELATION WITH INDICATORS OF METABOLIC DISTURBANCES.

Authors:  A Atanasova Boshku; D Ivanova Panova; B Zafirova Ivanovska
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Jul-Sep       Impact factor: 0.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.